Bone Marrow Transplantation News

CHICAGO — Extending anticoagulation beyond 3 months reduced risk for recurrent clots in patients with cancer, according to results presented at the ASCO Annual Meeting.

CHICAGO — Despite global variance in cancer drug prices, generic and patented drugs are less affordable in low-income countries, according to a pilot study presented at the ASCO Annual Meeting.

CHICAGO — Liquid biopsy identified genomic alterations in patients with advanced solid tumors at a similar rate to traditional tumor biopsy, according to data presented at the ASCO Annual Meeting.

The use of broad-spectrum antibiotics, particularly piperacillin-tazobactam and Primaxin, for the treatment of neutropenic fever in allogeneic hematopoietic stem cell transplantation recipients was associated with an increased risk for mortality caused by graft-versus-host disease, according to recent findings.

A novel scoring system appeared prognostic of outcome for patients with myelodysplastic syndrome undergoing HLA–matched or –mismatched allogeneic hematopoietic stem cell transplantation, according to the results of a validation study.

Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the greatest misapprehensions and oversight failures within the scientific research community,” according to authors of a study review published in American Journal of Clinical Oncology.

DKMS, an international nonprofit organization, founded World Blood Cancer Day in 2014.

An assessment tool comprised of clinically relevant questions and specific treatment information accurately predicted risk for chemotherapy toxicity in a majority of older patients with cancer, according to the results of a validation study.

The FDA approved the first in vitro diagnostic test used to monitor cytomegalovirus treatment in hematopoietic stem cell transplant recipients, according to a press release.

A single standard CT scan may increase the risk for fatal cancer in one of every 2,000 patients, according to FDA data.